Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. (YMAB): 3 pipeline candidates · ~10 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.5 months
D/E 0.34 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Y-mAbs Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$62.3M
Quarterly Burn
$22.4M
Runway
9.5 mo
Revenue
$19.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cd38-sada | Phase 1 |
| danyelza | Approved |
| gm-csf + naxitamab | Phase 2 |
Frequently asked questions
How many drug candidates are in Y-mAbs Therapeutics, Inc.'s pipeline?
Y-mAbs Therapeutics, Inc. (YMAB) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Y-mAbs Therapeutics, Inc.'s lead drug candidate?
Y-mAbs Therapeutics, Inc.'s most advanced tracked candidate is cd38-sada (Phase 1).
What is Y-mAbs Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Y-mAbs Therapeutics, Inc. has approximately 9.5 months of cash runway.
Who is the CEO of Y-mAbs Therapeutics, Inc.?
Michael Rossi is the chief executive officer of Y-mAbs Therapeutics, Inc. (YMAB).
Get the full picture on Y-mAbs Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.